Edward P Feener Selected Research

Prekallikrein

1/2022	Plasma Kallikrein Contributes to Intracerebral Hemorrhage and Hypertension in Stroke-Prone Spontaneously Hypertensive Rats.
11/2021	Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation.
1/2017	Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.
1/2017	The Effects of the Contact Activation System on Hemorrhage.
4/2016	A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.
10/2015	Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema.
2/2007	Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Edward P Feener Research Topics

Disease

12	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2019 - 01/2002
7	Hemorrhage 01/2022 - 02/2007
7	Macular Edema 12/2019 - 03/2006
5	Hypertension (High Blood Pressure) 01/2022 - 01/2002
5	Edema (Dropsy) 01/2019 - 12/2010
4	Thrombosis (Thrombus) 11/2021 - 04/2016
4	Hyperglycemia 01/2019 - 02/2011
4	Inflammation (Inflammations) 01/2016 - 02/2007
4	Insulin Resistance 06/2014 - 02/2005
3	Hereditary Angioedemas 01/2022 - 01/2022
3	Retinal Hemorrhage 01/2017 - 02/2007
3	Retinal Neovascularization 01/2016 - 03/2006
3	Leukostasis 02/2013 - 03/2006
2	Stroke (Strokes) 01/2022 - 01/2017
2	Cerebral Hemorrhage 01/2022 - 01/2017
2	Hematoma 01/2017 - 02/2011
2	Papilledema 01/2016 - 02/2007
2	Ischemia 09/2015 - 10/2006
2	Type 2 Diabetes Mellitus (MODY) 06/2014 - 02/2005
2	Obesity 06/2014 - 04/2008
2	Myocardial Ischemia (Ischemic Heart Diseases) 01/2012 - 04/2005
1	Pain (Aches) 01/2022
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2022
1	Neoplasms (Cancer) 11/2021
1	Low Vision (Subnormal Vision) 12/2019
1	Mitochondrial Diseases (Mitochondrial Disease) 06/2017
1	Wounds and Injuries (Trauma) 01/2017
1	Thrombotic Stroke 01/2017
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2017
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2017
1	Angioedema 01/2017
1	Venous Thrombosis (Deep-Vein Thrombosis) 04/2016
1	Carotid Artery Thrombosis 04/2016
1	Retinal Perforations 10/2015
1	Vascular System Injuries 03/2013
1	Ischemic Stroke 03/2012
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2012

Drug/Important Bio-Agent (IBA)

17	Plasma KallikreinIBA 01/2022 - 02/2009
12	Retinaldehyde (Retinal)IBA 01/2019 - 03/2006
7	PrekallikreinIBA 01/2022 - 02/2007
6	BradykininIBA 01/2022 - 02/2009
6	Proteins (Proteins, Gene)FDA Link 01/2017 - 02/2007
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 01/2002
5	Angiotensin IIIBA 08/2013 - 04/2005
4	Factor XII (Hageman Factor)IBA 11/2021 - 08/2010
4	ProteomeIBA 01/2019 - 02/2007
3	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 09/2007
3	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2017 - 02/2011
2	High-Molecular-Weight Kininogen (Kininogen, High Molecular Weight)IBA 01/2022 - 04/2016
2	AcidsIBA 01/2022 - 02/2009
2	sebetralstatIBA 01/2022 - 01/2022
2	Kininogens (Kininogen)IBA 01/2022 - 08/2010
2	Kallikreins (Kallikrein)IBA 04/2016 - 02/2007
2	Oxygen (Dioxygen)IBA 01/2016 - 03/2006
2	KininsIBA 10/2015 - 03/2013
2	Insulin (Novolin)FDA Link 08/2013 - 09/2007
2	Protein Kinase CIBA 08/2013 - 04/2005
2	Serine (L-Serine)FDA Link 08/2013 - 09/2007
2	Tyrosine (L-Tyrosine)FDA Link 08/2013 - 02/2005
2	candesartanIBA 02/2009 - 03/2006
1	SaltsIBA 01/2022
1	Hormones (Hormone)IBA 01/2022
1	Antisense OligonucleotidesIBA 01/2022
1	Lysine (L-Lysine)FDA Link 01/2022
1	protein kinase modulatorIBA 01/2022
1	Atrial Natriuretic Factor (ANF)IBA 01/2022
1	PlasminogenIBA 01/2022
1	Thromboplastin (Tissue Factor)IBA 11/2021
1	PolyphosphatesIBA 11/2021
1	CytokinesIBA 01/2019
1	Retinol-Binding Proteins (Retinoid Binding Proteins)IBA 01/2019
1	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 01/2019
1	ML-265IBA 06/2017
1	Messenger RNA (mRNA)IBA 06/2017
1	Pyruvate KinaseIBA 06/2017
1	Therapeutic UsesIBA 01/2017
1	Hemostatics (Antihemorrhagics)IBA 01/2017
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2017
1	Peptide Hydrolases (Proteases)FDA Link 04/2016
1	Rose BengalIBA 04/2016
1	EnzymesIBA 04/2016
1	Enzyme Precursors (Zymogens)IBA 04/2016
1	Factor XIIa (Coagulation Factor XIIa)IBA 04/2016
1	Serine Proteases (Serine Protease)IBA 01/2016
1	Thrombin FDA Link 09/2015
1	Blood Coagulation Factors (Coagulation Factor)IBA 09/2015
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 09/2015
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 08/2013
1	Fluorescein (Funduscein)FDA LinkGeneric 02/2013
1	isothiocyanic acidIBA 02/2013
1	Concanavalin AIBA 02/2013
1	Collagenases (Collagenase)FDA Link 02/2013
1	Acridine OrangeIBA 02/2013
1	LectinsIBA 02/2013
1	Protons (Proton)IBA 03/2012
1	ThioredoxinsIBA 01/2012

Therapy/Procedure

4	Intravitreal Injections 12/2019 - 02/2009
3	Thrombolytic Therapy 01/2022 - 01/2017
3	Therapeutics 01/2017 - 01/2012
1	Glycemic Control 01/2019